1982

Safeguard Scientifics deployed capital in Imreg, Inc., a company engaged in the research and development of immunomodulators. This capital deployment marked Safeguard’s first entrée into the field of biotechnology. Many scientific observers believed that biotechnology at the time was at the same developmental stage as the semiconductor industry in the mid 1960s.

Safeguard Scientifics investment in Imreg represented its initial participation in an industry that would have major commercial and medical impact in the years ahead.